BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CureDuchenne Appoints Michael Kelly as Chief Scientific Officer


12/14/2011 7:05:02 AM

NEWPORT BEACH, CA, DECEMBER 13, 2011: CureDuchenne, a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy, today announced the appointment of Dr. Michael G. Kelly as Chief Scientific Officer, a key scientific position within the Duchenne community. Kelly, a senior pharmaceutical executive, brings more than 25 years experience in drug discovery and development to the organization. He will help advance drug development programs and help identify new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.

In addition, Kelly will be responsible for CureDuchenne’s Drug Discovery and Development Program to help drive research to market for treatments and ultimately a cure for Duchenne. Before joining CureDuchenne, Kelly served as President and U.S. site head of Renovis, Inc. and has held senior positions at Amgen, Inc., Wyeth (Pfizer) and Wellcome (GlaxoSmithKline).

Kelly holds a PhD from the University of Southampton (U.K.), held research positions at the University of Michigan and University of Nottingham, is an inventor on more than 100 patents and is widely published in peer reviewed journals.

CureDuchenne, a national nonprofit organization located in Newport Beach, Calif., is gaining international attention for its efforts to raise funds and awareness for Duchenne – a devastating and lethal muscle disease in children. One in every 3,500 births results in a child being afflicted (mostly boys) with the disease. Over 24,000 boys are living with the disease in the United States alone, and most will not survive their teenage years.

The funds CureDuchenne raises support the most promising research projects aimed at treating and curing the disease with the help of its distinguished panel of Scientific Advisors from around the world. To date, seven research projects have made their way into human clinical trials with support from CureDuchenne. This accelerated push to move research from the lab into clinical trials could save the lives of those afflicted and give them hope for halting the progress of the disease. Very few health-related nonprofits have been as successful in being a catalyst for human clinical trials. CureDuchenne also works tirelessly to bring awareness to the disease through extensive outreach, promotions and celebrity endorsements.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES